Skip to main content
Premium Trial:

Request an Annual Quote

Galileo Genomics Closes $5.2M in Financing

This article has been corrected from a previous version, to reflect the currency conversions between Canadian and US dollars.

 

NEW YORK, Feb. 25 - Galileo Genomics of Montreal said today it had closed CA$7.7 million, ($5.2 million) in new financing.

 

The financing came in the form of two rounds, the first a $CA4.7 million ($3.15 million) round led by HBM Bioventures of Zurich, with contributions from Investissement Desjardins of Montreal, BTF of Amsterdam, MVI of London, and BioFund of Helsinki; and the second a $CA3.0 million ($2.0 million) capital equipment-based financing with MM Venture Partners.

 

Galileo is building a population genomics database based on Quebecfounder populations, and is analyzing the database for common diseases.

 

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.